We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 1ZTS market cap is 68.09B. The company's latest EPS is USD 5.5517 and P/E is 29.61.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.68B | 7.78B | 8.08B | 8.54B | 9.26B |
| Operating Income | 2.22B | 2.73B | 2.88B | 2.98B | 3.32B |
| Net Income | 1.64B | 2.04B | 2.11B | 2.34B | 2.49B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 13.61B | 13.9B | 14.93B | 14.29B | 14.24B |
| Total Liabilities | 9.84B | 9.36B | 10.52B | 9.3B | 9.47B |
| Total Equity | 3.77B | 4.54B | 4.4B | 4.99B | 4.77B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 2.13B | 2.21B | 1.91B | 2.35B | 2.95B |
| Investing | -572M | -458M | -883M | -777M | -315M |
| Financing | 123M | -1.86B | -904M | -3.11B | -2.66B |
| Market Cap | 68.09B |
| Price to Earnings Ratio | 29.61 |
| Price to Sales Ratio | 7.95 |
| Price to Cash Ratio | 37.05 |
| Price to Book Ratio | 15.43 |
| Dividend Yield | 1.43% |
| Shares Outstanding | 447.79M |
| Average Volume (1 week) | 107 |
| Average Volume (1 Month) | 187 |
| 52 Week Change | -9.76% |
| 52 Week High | 185.04 |
| 52 Week Low | 140.30 |
| Spread (Intraday) | 2.26 (1.48%) |
| Company Name | Zoetis Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.zoetis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
